Okuno Tomoko, Tsuruyama Tatsuaki, Haga Hironori, Ueda Mikiko, Takada Yasutsugu, Maetani Yoji, Manabe Toshiaki, Tamaki Keiji
Laboratory of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
J Hepatobiliary Pancreat Surg. 2009;16(6):802-7. doi: 10.1007/s00534-009-0110-x. Epub 2009 Apr 28.
BACKGROUND/PURPOSE: The applicability of the staging systems of hepatocellular carcinoma (HCC) to liver transplantation (LT) has not been fully evaluated. Therefore, we compared the HCC recurrence after LT as predicted by various staging systems, including the American Joint Committee on Cancer (AJCC) system 5th edition, the AJCC system 6th edition, the American Liver Tumor Study Group (ALTSG) system, and the Liver Cancer Study Group of Japan (LCSGJ) system.
A total of 108 patients who had HCC were classified according to these systems. We compared cumulative recurrence curves, recurrence-free survival curves, and overall survival curves of the systems estimated by Kaplan-Meier method. We compared cumulative event rates among different stages with the log-rank test for each staging system.
The log-rank test showed that the cumulative recurrence rates were different among different stages with a statistical significance for the staging systems except for the AJCC 5th edition system. Cumulative recurrence curves by the AJCC 6th edition system and the LCSGJ system showed better visual separation than the other two systems. With respect to recurrence-free survival and overall survival, no staging systems showed significant discriminative power.
The current AJCC tumor-node-metastasis staging and the LCSGJ system are superior in predicting HCC recurrence after LT.
背景/目的:肝细胞癌(HCC)分期系统在肝移植(LT)中的适用性尚未得到充分评估。因此,我们比较了包括美国癌症联合委员会(AJCC)第5版系统、AJCC第6版系统、美国肝脏肿瘤研究组(ALTSG)系统和日本肝癌研究组(LCSGJ)系统在内的各种分期系统预测LT术后HCC复发的情况。
共有108例HCC患者按照这些系统进行分类。我们比较了通过Kaplan-Meier法估计的各系统的累积复发曲线、无复发生存曲线和总生存曲线。我们对每个分期系统采用对数秩检验比较不同分期之间的累积事件发生率。
对数秩检验显示,除AJCC第5版系统外,其他分期系统不同分期之间的累积复发率存在差异,具有统计学意义。AJCC第6版系统和LCSGJ系统的累积复发曲线比其他两个系统显示出更好的视觉区分度。关于无复发生存和总生存,没有分期系统显示出显著的鉴别能力。
目前的AJCC肿瘤-淋巴结-转移分期和LCSGJ系统在预测LT术后HCC复发方面更具优势。